Pharmaceutical pollution in surface waters poses risks to human and ecosystem health. Wastewater treatment facilities are primary sources of pharmaceutical pollutants, but little is known about the factors that affect drugs entering the wastewater stream. This paper investigates the effects of student pharmaceutical use and disposal behaviors and an annual demographic shift on pharmaceutical po...

Pharmaceutical industry represents a range of industries with operation and processes as diverse as its product. Hence effluents coming from pharma industries vary from industry to industry. Thus it is almost impossible to describe a typical pharmaceutical effluent because of such diversity. Waste water is generally evaluated in terms of temp, pH, Total suspended solid (TSS), BOD, COD, Oil & gr...

The current Good Manufacturing Practice (cGMP) and effluent emission (use and disposal) regulations of the U.S. Food and Drug Administration (FDA) and manufacturing effluent discharge and emission regulations of the U.S. Environmental Protection Agency (U.S. EPA) require contained manufacture, use, and disposal of pharmaceuticals with the goal of minimizing the release of pharmaceutical chemica...

Human-derived pharmaceuticals have been identified entering surface waters in the United States through wastewater effluent. While there is ample literature about what each compound alone does to aquatic life, little is known about the effects aquatic life may experience from the exposure to many different pharmaceuticals present in the environment. More specifically, are the combination of pha...

Traces of active pharmaceutical ingredients (APIs) and other chemicals are demonstrated in effluents from sewage treatment plants (STPs) and they may affect quality of surface water and eventually drinking water. Treatment of effluents with granular activated carbon (GAC) or ozone to improve removal of APIs and other contaminants was evaluated at two Swedish STPs, Käppala and Uppsala (88 and 10...